Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Eric Pujade-Lauraine
Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
The Lancet Oncology
Oncology
Oncologic Trogocytosis of an Original Stromal Cells Induces Chemoresistance of Ovarian Tumours
PLoS ONE
Multidisciplinary
Related publications
Olaparib Combined With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
The Lancet Oncology
Oncology
ENGOT-ov-6/TRINOVA-2: Randomised, Double-Blind, Phase 3 Study of Pegylated Liposomal Doxorubicin Plus Trebananib or Placebo in Women With Recurrent Partially Platinum-Sensitive or Resistant Ovarian Cancer
European Journal of Cancer
Cancer Research
Oncology
CONFIRM: A Double-Blind, Placebo-Controlled Phase III Clinical Trial Investigating the Effect of Nivolumab in Patients With Relapsed Mesothelioma: Study Protocol for a Randomised Controlled Trial
Trials
Medicine
Pharmacology
Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial
The Lancet
Medicine
Etanercept in Alzheimer Disease: A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Trial
Neurology
Neurology
Photodynamic Therapy for Dysplastic Barrett's Oesophagus: A Prospective, Double Blind, Randomised, Placebo Controlled Trial
Gut
Gastroenterology
A Randomised, Double-Blind, Placebo-Controlled Multi-Centre Phase III Trial of XELIRI/FOLFIRI Plus Simvastatin for Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
Bumetanide in Hypokalaemic Periodic Paralysis: A Randomised, Double-Blind, Placebo Controlled Phase II Clinical Trial With a Crossover Design
Neuromuscular Disorders
Child Health
Neurology
Pediatrics
Perinatology
Genetics
Docetaxel and Dasatinib or Placebo in Men With Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised, Double-Blind Phase 3 Trial
The Lancet Oncology
Oncology
